Vera Therapeutics (NASDAQ:VERA) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Vera Therapeutics from “strong sell” to “sell,” a modest improvement that still reflects a negative view. Across analysts, the consensus rating is “Moderate Buy,” with an average price target of $74.93.
• Vera reported a third-quarter loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million, above the $3.42 million estimate.
• Analyst views remain mixed: Guggenheim lowered its price target to $66 while keeping a Buy rating, whereas JPMorgan raised its target to $83 and maintained an Overweight rating.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on VERA. Cantor Fitzgerald reissued an "overweight" rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Guggenheim dropped their target price on Vera Therapeutics from $76.00 to $66.00 and set a "buy" rating for the company in a report on Friday. TD Cowen reiterated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. JPMorgan Chase & Co. upped their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Vera Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $74.93.

Vera Therapeutics Price Performance

Shares of VERA opened at $29.78 on Friday. Vera Therapeutics has a fifty-two week low of $23.86 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The business's 50-day moving average is $31.60 and its 200-day moving average is $36.68. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.05 and a beta of 1.07.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, beating analysts' consensus estimates of ($1.62) by $0.32. The company had revenue of $10.28 million during the quarter, compared to the consensus estimate of $3.42 million. Equities research analysts expect that Vera Therapeutics will post -6.45 EPS for the current fiscal year.

Insider Activity

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares of the company's stock, valued at $8,704,028. This trade represents a 7.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Allworth Financial LP increased its stake in Vera Therapeutics by 66.3% in the third quarter. Allworth Financial LP now owns 1,515 shares of the company's stock valued at $49,000 after purchasing an additional 604 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Vera Therapeutics by 9.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 54,532 shares of the company's stock worth $1,761,000 after purchasing an additional 4,797 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Vera Therapeutics in the third quarter worth $32,000. Fifth Third Bancorp boosted its position in Vera Therapeutics by 49.8% in the third quarter. Fifth Third Bancorp now owns 165,245 shares of the company's stock valued at $5,336,000 after buying an additional 54,942 shares during the last quarter. Finally, Fulcrum Asset Management LLP acquired a new stake in Vera Therapeutics in the third quarter valued at $74,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company's research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera's lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.